Wave Life Sciences announced earlier this week that Suvodirsen has been granted fast track approval by the Federal Drug Administration (the drug regulator in the US).
Suvodirsen is a potential treatment for Duchenne that is designed to skip exon 51 of the dystrophin gene. This could help approximately 13% of people living with the condition (depending on the mutation type). The Fast Track designation is designed to facilitate the development of drugs that aim to treat serious conditions where there is an unmet need.
Wave has recently started a large phase 2/3 clinical trial of Suvodirsen to test it’s potential effectiveness. The trial be recruiting across many countries, and we will bring you more information soon.
Wave has also said that they are analysing the muscle biopsies from earlier trials, and hope to present the results later his year.
If you have any questions please contact Neil or call us on 02072508240.
